Compare ULBI & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULBI | INO |
|---|---|---|
| Founded | 1990 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.0M | 90.5M |
| IPO Year | 1995 | 1999 |
| Metric | ULBI | INO |
|---|---|---|
| Price | $6.46 | $1.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 48.1K | ★ 1.6M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $191,159,000.00 | $42,220,086.00 |
| Revenue This Year | $20.00 | $20,156.19 |
| Revenue Next Year | N/A | $421.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 16.24 | ★ 19.37 |
| 52 Week Low | $4.90 | $1.03 |
| 52 Week High | $9.51 | $2.86 |
| Indicator | ULBI | INO |
|---|---|---|
| Relative Strength Index (RSI) | 45.43 | 41.74 |
| Support Level | $6.19 | $1.03 |
| Resistance Level | $7.25 | $1.23 |
| Average True Range (ATR) | 0.36 | 0.06 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 16.75 | 22.92 |
Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company also designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.